Weiter zum Inhalt
Toggle navigation
English
English
Favoritenliste (
0
)
(Voll)
Kontakt
Mein Konto
Abmeldung
Mein Konto
Suche
Erweiterte Suche bearbeiten
Filter bei nächster Suche beibehalten
collection:"CTG"
Erweiterte Suche
Suchverlauf
Struktursuche
Narrative Service
Drug Overviews
Info Guide
/vufind/Search/Results?join=AND&bool0%5B%5D=AND&lookfor0%5B%5D=%22Adalimumab%22&type0%5B%5D=Subject&op0%5B%5D=OR&filter%5B%5D=collection%3ACTG
/vufind/Search/Results?join=AND&bool0%5B%5D=AND&lookfor0%5B%5D=%22Adalimumab%22&type0%5B%5D=Subject&op0%5B%5D=OR&filter%5B%5D=collection%3ACTG
Search /vufind/Search2/Results?join=AND&bool0%5B%5D=AND&lookfor0%5B%5D=%22Adalimumab%22&type0%5B%5D=Subject&op0%5B%5D=OR&filter%5B%5D=collection%3ACTG
PubPharm (34)
1
Increasing time between adalimumab injections in IBD patients. : Lengthening Adalimumab Dosing Interval in IBD patients in long term remission, theLADI study.
enthalten in:
WHO International Clinical Trials Registry Platform
| 2023
Wird geladen...
2
Lengthening Adalimumab Dosing Interval in quiescent Crohn’s disease patients : Lengthening Adalimumab Dosing Interval in quiescent Crohn’s disease patients
enthalten in:
WHO International Clinical Trials Registry Platform
| 2023
Wird geladen...
3
(English) Cost-effectiveness of new medicines (Mabthera and Orencia) compared to a second TNF blocking medicine, for patients with inadequate effect of a first TNF blocking medicine. (Dutch)Onderzoek naar de kosteneffectiviteit van nieuwe medicijnen (Mabthera en Orencia) vergeleken met een tweede TNF blokerend middel, voor patienten met onvoldoende effect van een eerste behandeling met TNF blokkerende middelen. : The cost-effectiveness of abatacept, rituximab or anti-TNF alpha for patients with rheumatoid arthritis.
enthalten in:
WHO International Clinical Trials Registry Platform
| 2023
Wird geladen...
4
Onderzoek naar non inferioriteit van afbouw en stop behandelstrategieën van adalimumab of etanercept bij patiënten met reumatoïde artritis: Kosten besparen tegen welke prijs? : Randomised controlled non-inferiority study of dose reduction and withdrawal strategies of adalimumab and etanercept in rheumatoid arthritis: Saving costs at what expense?
enthalten in:
WHO International Clinical Trials Registry Platform
| 2023
Wird geladen...
5
Dose decrease of biologics in psoriasis patients with low disease activity. : Tight control dose reductions of biologics in psoriasis patients with low disease activity: a randomized pragmatic trial.
enthalten in:
WHO International Clinical Trials Registry Platform
| 2023
Wird geladen...
6
Measuring infliximab and adalimumab blood levels in IBD patients, prospective observations from a single center compared to a time period before regular use of these measurements. : Therapeutic drug monitoring of TNF-alpha blockers in IBD, a prospective single center cohort experience compared to biologicals in the pre-TDM era
enthalten in:
WHO International Clinical Trials Registry Platform
| 2023
Wird geladen...
7
The influence of adalimumab on thiopurine metabolism in Crohn's disease patients. : The influence of adalimumab on thiopurine metabolism in Crohn's disease patients.
enthalten in:
WHO International Clinical Trials Registry Platform
| 2023
Wird geladen...
8
Increasing time between adalimumab injections in IBD patients. : Lengthening Adalimumab Dosing Interval in IBD patients in long term remission, theLADI study.
enthalten in:
WHO International Clinical Trials Registry Platform
| 2023
Wird geladen...
9
Lengthening Adalimumab Dosing Interval in quiescent Crohn’s disease patients : Lengthening Adalimumab Dosing Interval in quiescent Crohn’s disease patients
enthalten in:
WHO International Clinical Trials Registry Platform
| 2023
Wird geladen...
10
(English) Cost-effectiveness of new medicines (Mabthera and Orencia) compared to a second TNF blocking medicine, for patients with inadequate effect of a first TNF blocking medicine. (Dutch)Onderzoek naar de kosteneffectiviteit van nieuwe medicijnen (Mabthera en Orencia) vergeleken met een tweede TNF blokerend middel, voor patienten met onvoldoende effect van een eerste behandeling met TNF blokkerende middelen. : The cost-effectiveness of abatacept, rituximab or anti-TNF alpha for patients with rheumatoid arthritis.
enthalten in:
WHO International Clinical Trials Registry Platform
| 2023
Wird geladen...
1
2
3
4
Nächster »
[4]
Filter & Sortierung
Treffer pro Seite
10
20
50
Sortieren
Relevanz
Neueste zuerst
Älteste zuerst
Verfasser
Zeitschriftentitel
Bibliothek
Standort (Printmedien)
Verwandte Substanzen
Verwandte Substanzen werden ermittelt...
Verwandte Erkrankungen/Symptome
Verwandte Erkrankungen/Symptome werden ermittelt...
Verwandte Gene
Verwandte Gene werden ermittelt...
Systematic Reviews
Filter aufheben
Clinical Studies
Patente
Covid-19/SARS-CoV-2
Exclude Systematic Reviews
Exclude Clinical Studies
Exclude Patents
Medienart
34
Aufsätze
34
E-Artikel
34
E-Ressourcen
Zeitschriftentitel
30
WHO International Clinical Trials Registry Plat...
4
ClinicalTrials.gov
Thema
34
610
30
Study Type: Interventional
14
Recruitment Status: Not yet recruiting
11
Recruitment Status: Recruiting
6
Phase: Phase 4
5
Recruitment Status: Completed
4
Study Type: Observational non invasive
3
Phase: Phase 2
2
Medical Condition: Adalimumab has the indicatio...
2
Medical Condition: Adalimumab in treatment of r...
2
Medical Condition: Cette étude portera sur une...
2
Medical Condition: Crohn's DiseaseUlcerative Co...
2
Medical Condition: In The Netherlands, ~35.000 ...
2
Medical Condition: In early RA methotrexate and...
2
Medical Condition: Inflammatory bowel diseases,...
2
Medical Condition: Patients taking biologic med...
2
Medical Condition: RA patients fulfilling the 1...
2
Medical Condition: Rheumatoid Arthritis, Reumat...
2
Medical Condition: Rheumatoid Arthritis, adalim...
2
Medical Condition: To determine the efficacy of...
Alle anzeigen ...
weniger ...
Erscheinungszeitraum
23
2020-
11
2010-2019
Erscheinungsjahr(e)
Von:
Bis:
Sprache
28
Englisch
2
Niederländisch
2
Französisch
2
Deutsch
Haven't found what you're looking for?
Wird geladen...